M

Malin Corporation PLC
ISEQ:MLC

Watchlist Manager
Malin Corporation PLC
ISEQ:MLC
Watchlist
Price: 8.65 EUR Market Closed
Market Cap: 162.7m EUR
Have any thoughts about
Malin Corporation PLC?
Write Note

Net Margin
Malin Corporation PLC

0%
Current
0%
Average
0.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-1.1m
/
Revenue
0

Net Margin Across Competitors

Country IE
Market Cap 164.1m EUR
Net Margin N/A
Country US
Market Cap 1.2T USD
Net Margin
9%
Country US
Market Cap 202.3B USD
Net Margin
14%
Country US
Market Cap 166.6B USD
Net Margin
18%
Country KR
Market Cap 66.8T KRW
Net Margin
24%
Country CH
Market Cap 38.4B CHF
Net Margin
9%
Country US
Market Cap 38.8B USD
Net Margin
20%
Country US
Market Cap 36.3B USD
Net Margin
9%
Country US
Market Cap 27B USD
Net Margin
21%
Country US
Market Cap 24.1B USD
Net Margin
17%
Country CN
Market Cap 162B CNY
Net Margin
21%
No Stocks Found

Malin Corporation PLC
Glance View

Market Cap
164.1m EUR
Industry
Life Sciences Tools & Services

Malin Corp. Plc.invests and supports innovative life sciences companies, which develops exceptional science and technology to deliver transformative outcomes for patients. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The company went IPO on 2015-03-25. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, CG Oncology, Wren, KNOW Bio and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of hematological malignancies, including multiple myeloma, and solid tumours, like prostate cancer. The company is also developing two CAR-T therapies: autologous and allogeneic. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder-saving therapeutics for patients with bladder cancer.

MLC Intrinsic Value
10.81 EUR
Undervaluation 20%
Intrinsic Value
Price
M

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-1.1m
/
Revenue
0
What is the Net Margin of Malin Corporation PLC?

Based on Malin Corporation PLC's most recent financial statements, the company has Net Margin of 0%.